
GMR SOLUTIONS INC-A
GMRSNYSETrading Snapshot
- Day Range
- $11.78 โ $11.99
- 52-Week Range
- $10.26 โ $15.98
- Volume
- $2.12B
- Avg Volume
- $1.60B
- Shares Outstanding
- 54.0M
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $5.74B
- Last Q Revenue
- $1.46B
- P/E Ratio
- โ
- P/S Ratio
- โ
- EPS (TTM)
- โ
- Dividend Yield
- โ
Why Investors Own GMRS
- โHigh-growth profile โ revenue up +52.6% YoY with expanding US Equity exposure.
- โHealthy economics โ 65% gross margin and 12% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GMR SOLUTIONS INC-A
GMR Solutions Inc., headquartered in Lewisville, Texas, is a leading U.S.-based company specializing in comprehensive out-of-hospital healthcare and mobile clinical services. The organization delivers both emergency and non-emergency medical care. Beyond direct patient transport and treatment, their service portfolio extends to include tailored membership programs, dedicated standby medical support for special events, and significant contractual agreements. These include a national ambulance contract with the Federal Emergency Management Agency (FEMA), as well as numerous partnerships with state agencies and health systems, all aimed at streamlining emergency medical response efforts. GMR Solutions serves a diverse client base, encompassing hospital systems of all sizes (from large regional networks to smaller independent facilities), local communities, healthcare payors, public health organizations, and various governmental entities at local, state, and federal levels.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
GMR Solutions (GMRS) Price Target Increased by 14.29% to 20.40

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Niki BioSolutions (NASDAQ:NIKI) stock moved upwards by 44.7% to $13.01 during Thursday's pre-market session. The company's market cap stands at $73.2 million. Zhengye Biotechnology (NASDAQ:ZYBT) shares